Kura Oncology Inc (KURA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $713.90M
Last updated: Nov 17, 2026 at 11:05 AM ET
Kura Oncology Inc (KURA) Stock Forecast
Analysts expect Kura Oncology (KURA) to earn -$3.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $90.16M. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 18.8% |
| Buy | 12 | 75.0% |
| Hold | 1 | 6.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 122.3%.
- Fiscal year ending Dec 31, 2026
- -$3.14
- EPS consensus, revenue $90.16M
- Fiscal year ending Dec 31, 2027
- -$2.42
- EPS consensus, revenue $200.41M
- Next report
- Mar 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.14 | -$3.21 to -$3.07 | 4 | $90.16M | $86.70M to $94.42M | 13 |
| Dec 31, 2027 | -$2.42 | -$3.26 to -$1.75 | 10 | $200.41M | $139.26M to $473.00M | 14 |
Quarterly Estimates
The EPS consensus rises from -$0.86 for the quarter ending Dec 31, 2026 to -$0.69 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.86 | -$1.07 to -$0.72 | 17 | $31.68M | $21.53M to $86.00M | 17 |
| Mar 31, 2027 | -$0.69 | -$0.79 to -$0.60 | 3 | $41.77M | $33.30M to $47.00M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.23.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.14 | -$3.20 | -$3.17 | -$3.16 | -$3.23 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.42 | -$2.34 | -$2.35 | -$2.30 | -$2.30 | N/A |
| Quarter ending Mar 31, 2027 | -$0.69 | -$0.68 | -$0.68 | -$0.67 | -$0.72 | N/A |
Frequently Asked Questions About KURA
What is the KURA stock forecast?
Consensus analyst estimates put Kura Oncology's EPS at -$3.14 for the fiscal year ending Dec 31, 2026, on revenue of $90.16M. The consensus rating from 16 analysts is Buy.
How do analysts rate KURA stock?
Of 16 analysts covering Kura Oncology, 3 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KURA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.14, with estimates from -$3.21 to -$3.07 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.42, with estimates from -$3.26 to -$1.75 from 10 analysts.
What revenue do analysts expect from Kura Oncology next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $90.16M, with estimates from $86.70M to $94.42M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $200.41M, with estimates from $139.26M to $473.00M.
How many analysts cover KURA?
16 analysts rate Kura Oncology stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KURA pages: Overview, Earnings, Forecast, Financials, Competitors